These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23372543)

  • 1. A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.
    Glazer J; Huskamp HA; McGuire TG
    Forum Health Econ Policy; 2012 Mar; 15(2):. PubMed ID: 23372543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constraints on Formulary Design Under the Affordable Care Act.
    Andersen M
    Health Econ; 2017 Dec; 26(12):e160-e178. PubMed ID: 28233420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states.
    Khan S; Sylvester R; Scott D; Pitts B
    J Manag Care Pharm; 2008 Oct; 14(8):780-9. PubMed ID: 18983207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating price elasticities of demand for pain relief drugs: evidence from Medicare Part D.
    Soni A
    Int J Health Econ Manag; 2024 Dec; 24(4):481-515. PubMed ID: 39093341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new medicare drug benefit: formularies and their potential effects on access to medications.
    Huskamp HA; Keating NL
    J Gen Intern Med; 2005 Jul; 20(7):662-5. PubMed ID: 16050866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    Cassels A; Law MR
    CMAJ Open; 2019; 7(3):E472-E477. PubMed ID: 31320330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Patient Migration Patterns and Related Health Care Costs Within a National Medicare Advantage Prescription Drug Plan After Implementation of an Oxycodone HCl Extended-Release Access Restriction.
    Chen CC; De AP; Sweet B; Wade RL
    J Manag Care Spec Pharm; 2017 Aug; 23(8):902-912. PubMed ID: 28737985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perverse incentives in the Medicare prescription drug benefit.
    McAdams D; Schwarz M
    Inquiry; 2007; 44(2):157-66. PubMed ID: 17850042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
    Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
    Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.